| 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 26,6 k € | +250.4% | 7,6 k € | -74.7% | 30,0 k € | 0.0% | 30,0 k € | +2.7% | 29,2 k € | +82.6% | 16,0 k € | -15.8% | 19,0 k € | +375.0% | 4,0 k € | -75.0% | 16,0 k € | — | 18,0 k € | +5.9% | 17,0 k € | ||||
| Gross margin | -5,6 k € | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||
| EBITDA | -10,9 k € | -175.3% | 14,5 k € | +246.0% | -10,0 k € | -397.2% | 3,3 k € | -50.4% | 6,8 k € | +676.3% | 870,2 € | +123.4% | -3,7 k € | -3385.1% | -106,8 € | +94.2% | -1,8 k € | -12.3% | -1,6 k € | +35.0% | -2,5 k € | -281.6% | -664,2 € | -111.2% | 5,9 k € | |
| Operating profit | -10,9 k € | +86.0% | -78,0 k € | -683.7% | -10,0 k € | -397.2% | 3,3 k € | -50.4% | 6,8 k € | +676.3% | 870,2 € | +123.4% | -3,7 k € | -3385.1% | -106,8 € | +94.2% | -1,8 k € | -12.3% | -1,6 k € | +35.0% | -2,5 k € | -281.6% | -664,2 € | -111.2% | 5,9 k € | |
| Profit/loss | -11,2 k € | +94.9% | -221,3 k € | -2311.5% | -9,2 k € | -386.3% | 3,2 k € | -52.3% | 6,7 k € | +836.3% | 717,1 € | +118.4% | -3,9 k € | -2306.1% | -161,6 € | +90.9% | -1,8 k € | -1.9% | -1,7 k € | +28.4% | -2,4 k € | -324.6% | -574,4 € | -109.5% | 6,0 k € | |
| Equity | -43,3 k € | -34.8% | -32,1 k € | -117.0% | 189,1 k € | +213.7% | 60,3 k € | +5.6% | 57,1 k € | +13.3% | 50,4 k € | +1.4% | 49,7 k € | -7.3% | 53,5 k € | -0.3% | 53,7 k € | -3.2% | 55,5 k € | -3.1% | 57,2 k € | -4.1% | 59,7 k € | -1.0% | 60,2 k € | |
| Total assets | 2,2 k € | -4.8% | 2,3 k € | -99.1% | 258,3 k € | +27.0% | 203,4 k € | +46.0% | 139,3 k € | +37.4% | 101,4 k € | +46.9% | 69,0 k € | +0.6% | 68,6 k € | +23.3% | 55,6 k € | -9.2% | 61,2 k € | +4.5% | 58,6 k € | -5.4% | 61,9 k € | -7.8% | 67,2 k € | |
| Cash | 2,2 k € | +192.2% | 760,1 € | -99.5% | 146,4 k € | +44.6% | 101,2 k € | +156.7% | 39,4 k € | +1214.6% | 3,0 k € | +200.7% | 997,4 € | -96.7% | 30,5 k € | -43.1% | 53,6 k € | +8.4% | 49,4 k € | -7.9% | 53,7 k € | -7.6% | 58,0 k € | -3.0% | 59,8 k € | |
| Debts | 39,7 k € | +18.1% | 33,6 k € | -51.4% | 69,1 k € | -51.7% | 143,1 k € | +74.1% | 82,2 k € | +61.2% | 51,0 k € | +163.7% | 19,3 k € | +28.8% | 15,0 k € | +690.4% | 1,9 k € | -67.0% | 5,7 k € | +1605.1% | 337,1 € | -73.2% | 1,3 k € | -78.8% | 5,9 k € | |
Public limited company · Gembloux · incorporated on 11/05/2001
Company — Voluntary dissolution - liquidation.
Public limited company loss-making in the latest fiscal year. Cash position rising (+192.2%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
BIOTREATMENT is a Public limited company incorporated in 2001. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gembloux.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette